Login to Your Account



Arsanis to carry pneumonia prevention MAb through phase II with $45.5M series D

By Michael Fitzhugh
Staff Writer

Wednesday, April 26, 2017

Arsanis Inc., an infectious disease specialist developing a targeted monoclonal antibody to prevent Staphylococcus aureus pneumonia, has closed on a $45.5 million series D financing that will help it complete a phase II trial of candidate ASN-100.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription